<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01735318</url>
  </required_header>
  <id_info>
    <org_study_id>Ipca/ARL-10/384</org_study_id>
    <nct_id>NCT01735318</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting Condition</brief_title>
  <official_title>A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IPCA Laboratories Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IPCA Laboratories Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, balanced, open Label, two-treatment, two-period, two-sequence, single&#xD;
      dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence&#xD;
      between Test Product and the corresponding Reference Product under fasting condition in&#xD;
      normal, healthy, adult, male and female human subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of this pivotal study was to assess the bioequivalence between Test Product:&#xD;
      Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India and the corresponding Reference&#xD;
      Product: Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA, under&#xD;
      fasting condition in normal, healthy, adult, male and female human subjects in a randomized&#xD;
      crossover study.&#xD;
&#xD;
      The study was conducted with 40 healthy adult subjects. In each study period, a single 40 mg&#xD;
      dose of either test or reference was administered to the subjects as per the randomization&#xD;
      schedule in each study period with about 240 mL of water at ambient temperature in sitting&#xD;
      position.&#xD;
&#xD;
      The duration of the clinical phase was approximately 19 days including washout period of 15&#xD;
      days between administrations of study drug in each study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>2 months</time_frame>
    <description>Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hours post dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>2 months</time_frame>
    <description>Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hours post dose</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Lisinopril Tablets 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zestril® (Lisinopril) 40 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril Tablets 40 mg</intervention_name>
    <description>40 mg tablet once a day</description>
    <arm_group_label>Lisinopril Tablets 40 mg</arm_group_label>
    <other_name>Test Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>40 mg tablet once a day</description>
    <arm_group_label>Zestril® (Lisinopril) 40 mg Tablets</arm_group_label>
    <other_name>Zestril® (Lisinopril) 40 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and non pregnant female human subjects, age in the range of 18 - 45 years.&#xD;
&#xD;
          2. Body weight within ± 15% of ideal weight as related to height and body frame according&#xD;
             to Life Insurance Corporation (LIC) Chart.&#xD;
&#xD;
          3. Subjects with normal findings as determined by baseline history, physical examination&#xD;
             and vital sign examination (blood pressure, pulse rate, respiration rate and axillary&#xD;
             temperature).&#xD;
&#xD;
          4. Subjects with clinically acceptable findings as determined by haemogram, biochemistry,&#xD;
             urinalysis and 12 lead ECG.&#xD;
&#xD;
          5. Willingness to follow the protocol requirements especially abstaining from xanthine&#xD;
             containing food or beverages (chocolates, tea, coffee or cola drinks) or grapefruit&#xD;
             juice, any alcoholic products, the use of cigarettes and tobacco products for 48 hours&#xD;
             prior to dosing until after the last blood sample collection in each study period and&#xD;
             adherence to food, fluid and posture restrictions.&#xD;
&#xD;
          6. No history of significant alcoholism.&#xD;
&#xD;
          7. No history of drug abuse (benzodiazepines and barbiturates) for the last one month and&#xD;
             other illegal drugs for the last 6 months.&#xD;
&#xD;
          8. Non-smokers were included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of hypersensitivity to Lisinopril or related drugs.&#xD;
&#xD;
          2. Requiring medication for any ailment having enzyme-modifying activity in the previous&#xD;
             28 days, prior to dosing day.&#xD;
&#xD;
          3. Subjects who have taken prescription medications or over-the-counter products&#xD;
             (including vitamins and minerals) within 14 days prior to administration of&#xD;
             Investigational Product.&#xD;
&#xD;
          4. Any medical or surgical conditions, which might significantly interfere with the&#xD;
             functioning of gastrointestinal tract, blood-forming organs etc.&#xD;
&#xD;
          5. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,&#xD;
             metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric&#xD;
             diseases.&#xD;
&#xD;
          6. Participation in a clinical drug study or bioequivalence study 90 days prior to&#xD;
             present study.&#xD;
&#xD;
          7. History of malignancy or other serious diseases.&#xD;
&#xD;
          8. Blood donation 90 days prior to the commencement of the study.&#xD;
&#xD;
          9. Subjects with positive HIV tests, HBsAg or Hepatitis-C tests.&#xD;
&#xD;
         10. Found positive in breath alcohol test.&#xD;
&#xD;
         11. Found positive in urine test for drug abuse.&#xD;
&#xD;
         12. History of problem in swallowing.&#xD;
&#xD;
         13. Any contraindication to blood sampling.&#xD;
&#xD;
         14. Found positive serum Beta- hCG (Human Chorionic Gonadotropin) test.&#xD;
&#xD;
         15. Lactating women (currently breast feeding).&#xD;
&#xD;
         16. Female subjects not confirming to using birth control measures, from the date of&#xD;
             screening until the completion of the study. Abstinence, barrier methods (condom,&#xD;
             diaphragm, etc.) were acceptable. Use of hormonal contraceptives either oral or&#xD;
             implants.&#xD;
&#xD;
         17. Female subjects whose menstruation cycle coincided with the study periods.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Suhas Khandave, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accutest Research Lab (I) Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accutest Research Lab (I) Pvt. Ltd.</name>
      <address>
        <city>Navi-Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>November 5, 2012</study_first_submitted>
  <study_first_submitted_qc>November 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

